In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …

Measuring immune correlates of disease acquisition and protection in the context of a clinical
trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing …

Pathogen-associated molecular patterns (PAMPs) are stand-alone immunomodulators or ‘danger
signals,’ that are increasingly recognized as critical components of many modern …

The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA…

The state of areflexia and muscle weakness that immediately follows a spinal cord injury (SCI)
is gradually replaced by the recovery of neuronal and network excitability, leading to both …

In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the US, Chile,
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% …

Objective To estimate the frequency of chronic joint pain after infection with chikungunya virus
in a Latin American cohort. Methods A cross‐sectional follow‐up of a prospective cohort of …

Objective To determine if chikungunya virus persists in synovial fluid after infection, potentially
acting as a causative mechanism of persistent arthritis. Methods We conducted a cross‐…

The PALM trial in the Democratic Republic of the Congo identified a statistically significant
survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute …